Company: PRI
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029882
Chunk: 225

Company: Primerica, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 12
Chunk 225
---
Securities Authorized for Issuance Under Equity Compensation Plans

We have two compensation plans under which our equity securities are authorized for issuance. The Primerica, Inc. 2020 Omnibus Incentive Plan was approved by our stockholders in May 2020. The Primerica, Inc. Stock Purchase Plan for Agents and Employees was approved by our sole stockholder in March 2010. The following table sets forth certain information relating to these equity compensation plans at December 31, 2024. 

    Number of securitiesto be issued uponexercise ofoutstanding options,warrants and rights

    Weighted averageexercise price ofoutstanding options,warrants and rights

    Number of securitiesremaining availablefor future issuance

    Equity compensation plans approved by stockholders:

    Primerica, Inc. Second Amended and Restated 2020 Omnibus    Incentive Plan
     
    184,561
     
    (1)
     
    $
    -
     
    (2)

    1,117,745
     
    (3)

    Primerica, Inc. Stock Purchase Plan for Agents and    Employees
     
    -

    -

    1,612,719
     
    (4)

    Total
     
    184,561

    $
    -

    2,730,464

    Equity compensation plans not approved by stockholders
    n/a

    n/a

    n/a

(1)Consists of 125,942 shares of our common stock to be issued in connection with unvested RSUs. Also includes 58,619 shares of our common stock to be issued to certain executive officers in connection with outstanding PSUs if the Company achieves the targeted level of performance specified in the award agreement over a three-year period. Based on the actual ROAE and EPS growth (if applicable) achieved within the three-year performance period ended December 31, 2024, recipients of the 2022 PSU awards will receive 28,884 shares of our common stock compared with the targeted 26,475 shares on the vesting date of March 1, 2025. See Note 14 (Stockholders’ Equity) and Note 16 (Share-Based Transactions) to our consolidated financial statements included elsewhere in this report for more information on the equity awards outstanding. 

(2)At December 31, 2024, there were no outstanding stock options under our equity compensation plans.

(3)